Intellia’s Crispr experimental gene-editing therapy cut levels of an abnormal liver protein in interim, early-stage trial results https://t.co/p2Fl7ssI5v— Bloomberg (@business) February 28, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


